[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20080187A1 - Agonistas receptores de eritropoietina - Google Patents

Agonistas receptores de eritropoietina

Info

Publication number
PE20080187A1
PE20080187A1 PE2007000455A PE2007000455A PE20080187A1 PE 20080187 A1 PE20080187 A1 PE 20080187A1 PE 2007000455 A PE2007000455 A PE 2007000455A PE 2007000455 A PE2007000455 A PE 2007000455A PE 20080187 A1 PE20080187 A1 PE 20080187A1
Authority
PE
Peru
Prior art keywords
receptor agonists
erythropoietin receptor
antibody
erythropoyetin
erythroblasts
Prior art date
Application number
PE2007000455A
Other languages
English (en)
Inventor
Ai Ching Lim
Christopher Mehlin
Luis Borges
Randal R Ketchem
Hongxing Zhou
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20080187A1 publication Critical patent/PE20080187A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO CON LA SIGUIENTE SECUENCIA AMINOACIDICA ID NO.1, EL CUAL COMPRENDE UNA REGION VARIABLE DE CADENA SIMPLE QUE PUEDE SER SEC ID NO.3,4,5,6, 68, 90, 112, ENTRE OTROS, O FUSIONADO A UN Fc QUE PUEDE SER IgG1, IgG2, IgG3, IgG4. DICHO ANTICUERPO SE UNE AL RECEPTOR DE ERITROPOYETINA HUMANO, SIENDO UTILES EN LA ESTIMULACION Y DIFERENCIACION DE ERITROBLASTOS E INHIBICION DE LA APOPTOSIS DE EN LAS CELULAS PROGENITORAS DE LA ERITRO
PE2007000455A 2006-04-14 2007-04-13 Agonistas receptores de eritropoietina PE20080187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79217406P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
PE20080187A1 true PE20080187A1 (es) 2008-03-10

Family

ID=38610179

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000455A PE20080187A1 (es) 2006-04-14 2007-04-13 Agonistas receptores de eritropoietina

Country Status (10)

Country Link
US (1) US20080124340A1 (es)
EP (1) EP2007812A2 (es)
JP (1) JP2009533057A (es)
AR (1) AR060440A1 (es)
AU (1) AU2007238704A1 (es)
CA (1) CA2649384A1 (es)
MX (1) MX2008013201A (es)
PE (1) PE20080187A1 (es)
TW (1) TW200808822A (es)
WO (1) WO2007120766A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
WO2009046313A2 (en) * 2007-10-05 2009-04-09 University Of Maryland, Baltimore Novel compositions and methods for stimulating erythropoiesis in a mammal
SG172927A1 (en) * 2009-01-15 2011-08-29 Hoffmann La Roche Antibodies against human epo receptor
WO2010111282A1 (en) * 2009-03-24 2010-09-30 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
AU2013309272B2 (en) * 2012-08-31 2017-03-09 Richard A. Lerner Methods and compositions related to modulators of eukaryotic cells
SG11201503567SA (en) 2012-12-05 2015-06-29 Novartis Ag Compositions and methods for antibodies targeting epo
JP2017517272A (ja) * 2014-03-28 2017-06-29 ニューヨーク・ユニバーシティ Ｆｇｆ２３融合タンパク質
WO2016018883A1 (en) * 2014-07-29 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Tuning dimeric receptor signaling with extracellular ligands that alter receptor orientation and proximity upon binding
US20180230540A1 (en) 2015-08-12 2018-08-16 Novartis Ag Methods of treating ophthalmic disorders
WO2017068192A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain cd27-receptor agonist proteins
US10233255B2 (en) 2016-04-25 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind STAT3
AU2021377609A1 (en) * 2020-11-10 2023-06-08 The Scripps Research Institute Antibodies for opioid treatments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US6998124B1 (en) * 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
EP2007813A2 (en) * 2006-04-14 2008-12-31 Amgen Inc. Agonist erythropoietin receptor antibodies

Also Published As

Publication number Publication date
AU2007238704A1 (en) 2007-10-25
WO2007120766A3 (en) 2008-05-29
US20080124340A1 (en) 2008-05-29
EP2007812A2 (en) 2008-12-31
JP2009533057A (ja) 2009-09-17
MX2008013201A (es) 2008-10-22
CA2649384A1 (en) 2007-10-25
TW200808822A (en) 2008-02-16
WO2007120766A2 (en) 2007-10-25
AR060440A1 (es) 2008-06-18

Similar Documents

Publication Publication Date Title
PE20080187A1 (es) Agonistas receptores de eritropoietina
PE20110771A1 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
CU24058B1 (es) Antagonistas de pcsk9
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20110382A1 (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
PE20090711A1 (es) Region constante de anticuerpo mutante
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
NO20092121L (no) Humaniserte anti-faktor D-antistoffer og anvendelser derav
PE20090145A1 (es) Moleculas de enlace de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
CR7875A (es) Variantes de inmunoglobina y usos de esto
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MA29975B1 (fr) Antagonistes de la neuropiline
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
ES2633597T3 (es) Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
CR10347A (es) Anticuerpos contra el peptidob-amiloide
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119

Legal Events

Date Code Title Description
FC Refusal